# Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease

> **NCT07750158** · PHASE3 · RECRUITING · sponsor: **Exelixis** · enrollment: 600 (estimated)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** Zanzalintinib
- **BIOLOGICAL:** Pembrolizumab (+) Berahyaluronidase alfa
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07750158
- **Lead sponsor:** Exelixis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-08-25
- **Primary completion:** 2030-04-05
- **Final completion:** 2030-04-05
- **Target enrollment:** 600 (ESTIMATED)
- **Last updated:** 2026-09-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07750158

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07750158, "Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07750158. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*